Lee K H
Natural Products Laboratory, School of Pharmacy, University of North Carolina at Chapel Hill, 27599-7360, USA.
Public Health Nutr. 2000 Dec;3(4A):515-22. doi: 10.1017/s1368980000000604.
Issues concerning the past and future development of medicinal herbs from Chinese medicine (CM) are addressed in this paper. In the Western world, medicinal herbs are becoming increasingly popular and important in the public and scientific communities. In contrast to their regulated status in China and other countries, herbal medicines are regarded as dietary supplements in the US. Accordingly, research must continue worldwide to identify and improve the efficacy of the active principals of herbs both singly and in combination -- from active ingredients, active fractions, and active herbal formulations. While Western medicine currently employs pure, single compounds, either natural or synthetic, CM has long used multiple combinations of compounds in the form of processed natural products, primarily medicinal herbs, to treat and relieve the symptoms of many different human diseases. CM may have fewer and less severe side effects than single pure drugs, making CM especially attractive to the consumer. In effect, CM's focus on combination therapy does serve both ancient and modern theories. However, research using modern analytical and chemical techniques is needed to ensure efficacy and safety, to provide qualitative and quantitative analyses for dietary supplements, and to develop new, effective and safe world-class drugs. Drug design is an iterative process. Bioactivity-directed fractionation and isolation identify active natural compounds from single herbs or formulations. These lead structures can be chemically modified and improved through knowledge of structure--activity relationship, mechanism of action, drug metabolism, molecular modelling and combinatorial chemistry studies. Finally, efficacy and toxicity determination as well as clinical trials can contribute to the generation of new drugs from CM. To continue the legacy of CM, as well as the worldwide uses of other medicinal herbs, continued investigation of active formulations, bioactive fractions, and isolated compounds is critical to drug development in the 21st century.
本文探讨了中药药材过去与未来的发展问题。在西方世界,草药在公众和科学界正变得越来越受欢迎且重要。与在中国和其他国家受到监管的情况不同,草药在美国被视为膳食补充剂。因此,全球范围内必须继续开展研究,以确定并提高草药单一成分及组合成分(从活性成分、活性部位到活性草药制剂)的功效。虽然现代医学目前使用的是纯净的单一化合物,无论是天然的还是合成的,但中药长期以来一直以加工后的天然产物(主要是草药)的形式使用多种化合物组合来治疗和缓解多种不同人类疾病的症状。与单一纯药物相比,中药的副作用可能更少且更不严重,这使得中药对消费者特别有吸引力。实际上,中药对联合疗法的关注确实符合古代和现代理论。然而,需要运用现代分析和化学技术进行研究,以确保疗效和安全性,为膳食补充剂提供定性和定量分析,并开发新的、有效且安全的世界级药物。药物设计是一个迭代过程。生物活性导向的分级分离和分离可从单一草药或制剂中鉴定出活性天然化合物。通过了解构效关系、作用机制、药物代谢、分子建模和组合化学研究,这些先导结构可以进行化学修饰和改进。最后,疗效和毒性测定以及临床试验有助于从中药中开发新药。为了延续中药的传统,以及全球对其他草药的使用,持续研究活性制剂、生物活性部位和分离出的化合物对于21世纪的药物开发至关重要。